Dr. Figlin on lessons from CANTATA study of telaglenastat/cabozantinib in mRCC

Robert A. Figlin, MD, deputy director, Cedars-Sinai Cancer, discusses results from the phase 2 CANTATA study of cabozantinib (Cabometyx) plus either the novel glutaminase inhibitor telaglenastat (CB-839) or placebo in patients with advanced/metastatic renal cell carcinoma (mRCC) who progressed on immune checkpoint inhibitors or antiangiogenic therapies. Results presented at the 2021 ASCO Annual Meeting showed that the addition of telaglenastat did not improve the efficacy of cabozantinib in mRCC. In the video, Figlin explains key lessons learned from the results.